Fund factsheetFundFacts API
Issuer iSharesFigures as of 2026-10-05Generated 6 Oct 2026

iShares Nasdaq US Biotechnology UCITS ETF

IE00BYXG2H39ETF

The Share Class is a share class of a Fund which aims to achieve a return on your investment, through a combination of capital growth and income on the Fund’s assets, which reflects the return of the NASDAQ Biotechnology Index, the Fund’s benchmark index (Index).

Growth of 100

1001502002019202120232025
Fund217NASDAQ Biotechnology NET Index220
2017-10 → 2026-10 · rebased to 100

Key facts

TER0.35%
Fund sizeUSD 1.3bn
Inception2017-10-19
Holdings251
CurrencyUSD
DistributionAccumulating

Top holdings

  1. 01GILEAD SCIENCES8.01%
  2. 02AMGEN INC7.58%
  3. 03VERTEX PHARMACEUTICALS7.48%
  4. 04MODERNA5.38%
  5. 05REGENERON PHARMACEUTICALS4.87%
  6. 06REVOLUTION MEDICINES2.95%
  7. 07ILLUMINA INC2.94%
  8. 08BIOGEN2.19%
  9. 09ALNYLAM PHARMACEUTICALS1.95%
  10. 10ROIVANT SCIENCES LTD1.71%

Sectors

100%Health Care
  • Health Care99.8%

Countries

  1. United States94.1%
  2. Belgium1.7%
  3. China1.1%
  4. France0.9%
  5. Germany0.8%
  6. Canada0.3%
  7. United Kingdom0.3%
  8. Denmark0.3%
  9. Netherlands0.1%
  10. Iceland0.1%

Asset allocation

100%Equity
  • Equity99.8%
  • Cash0.2%
  • Cash Collateral and Margins0.0%

Risk & profile

1
2
3
4
5
6
7
Lower risk · lower rewardHigher risk · higher reward
United States Health Care Equity
RiskHighValuationGrowthConcentrationBalancedRegionUnited StatesSectorHealth Care

Calendar-year returns

+25.9%2020−0.4%2021−10.5%2022+4.2%2023−1.0%2024+32.9%2025
Fund NASDAQ Biotechnology NET Index

Annualised returns

PeriodFundIndexDiff
1 Year+38.07%+38.46%−0.39%
3 Years p.a.+21.64%+21.87%−0.23%
5 Years p.a.+7.21%+7.40%−0.19%
Since Inception+8.23%+8.45%−0.22%

Risk & valuation metrics

Volatility 3y17.4%
Sharpe 3y0.97
Max drawdown-23.9%
P/E ratio25.3x

Figures as of 2026-10-05. Data from FundFacts API; not investment advice.